Why this trial matters : First ADC to move into the 1L HER2+ metastatic setting Breaks a decade-long treatment paradigm in first-line breast cancer care Confirms ADCs as frontline platforms, not just late-line salvage therapies Roche Giredestrant Delivers the First Phase III Win for an Oral SERD in Early Breast Cancer Roches oral SERD giredestrant reduced the risk of invasive disease recurrence versus standard endocrine therapy in the Phase III lidERA trial in ER-positive, HER2-negative early breast cancer, marking the first major advance in adjuvant endocrine therapy in decades
doi: Mennella I, Fogliano V, Ferracane R, Arlorio M, Pattarino F, Vitaglione P
Reconstitution Guide (Step-by-Step) This is where people mess up most often and the errors usually compound
Its an exciting time a bit of a scary time but its also the time when the medical strategies Ive been taking for granted get called into question
10.22038/ijbms.2023.68487.14937 76 MullinsP
CharbonnelBKarasikALiuJWuMMeiningerGSitagliptin StudyG
